First Reported Use of the Repositionable Lotus Valve System for a Failing Surgical Aortic Bioprosthesis  by McCormick, Liam M. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S VO L . 8 , N O . 2 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 4 . 0 9 . 0 2 0IMAGES IN INTERVENTIONFirst Reported Use of the Repositionable
Lotus Valve System for a Failing
Surgical Aortic Bioprosthesis
Liam M. McCormick, MBBS, Robert Gooley, MBBS, Siobhan Lockwood, MBBS, Ian T. Meredith, AM, MBBS, PHDA n 80-year-old man with a history of atrialﬁbrillation (on warfarin) and signiﬁcantshort-term memory impairment presented
with symptoms of acute decompensated cardiac
failure 8 years after undergoing surgical aortic
valve replacement with a 25-mm Carpentier-
Edwards SAV bioprosthesis (Edwards Lifesciences,
Irvine, California) inserted for severe aortic steno-
sis. Transesophageal echocardiography (TEE) de-
monstrated severe valvular aortic regurgitation
(AR) (Figure 1A) with a borderline dilated left ven-
tricle and normal ejection fraction. In view of
comorbidities and general frailty, he was deemed
to be at high surgical risk by the heart team, and
therefore, transcatheter aortic valve replacement
(TAVR) was recommended.
Fluoroscopic and echocardiographic guidance was
used to position a 23-mm Lotus device (Boston Scien-
tiﬁc, Natick, Massachusetts). Initial attempts at posi-
tioning were too low (Figure 1B), and so after partial
resheathing (Figure 1C), the device was deployed
optimally within the bioprosthesis, extending 3 mm
into the left ventricular outﬂow tract (Figure 1D).
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no coronary obstruction.
Valve-in-valve (VIV) TAVR has been shown to be
a feasible and clinically effective approach to the
management of patients with degenerated surgical
aortic bioprostheses. However, with the use of
Edwards SAPIEN (Edwards Lifesciences) and Core-
Valve (Medtronic, Minneapolis, Minnesota) devices,
VIV TAVR is associated with a high rate of malposi-
tioning (15%), which may necessitate attempts at
device retrieval, or implantation of a second TAVR
device (1). We report here for the ﬁrst time a suc-
cessful VIV TAVR procedure using the Lotus Valve
System. Its unique design enables repositioning,
resheathing, and retrieval, even in the fully expanded
and functioning position. These features may be of
particular use in cases where the potential risk of
device malpositioning is high.
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FIGURE 1 Intraprocedural TEE and Fluoroscopy
(A) Pre-procedural severe valvular bioprosthetic aortic regurgitation. Initial positioning of the 23-mm Lotus device was too low (B), so partial
resheathing was performed (C), allowing optimal ﬁnal positioning within the bioprosthesis (D). (E) No signiﬁcant aortic regurgitation
post-procedure. TEE ¼ transesophageal echocardiography.
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